UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Esperion Theraptc (ESPR)

Esperion Theraptc (ESPR)
1.2500 x 23 1.3800 x 4
Pre-market by (Cboe BZX)
1.3900 -0.0200 (-1.42%) 04/02/25 [NASDAQ]
1.2500 x 23 1.3800 x 4
Pre-market 1.3500 -0.0400 (-2.88%) 04:02 ET
Quote Overview for Wed, Apr 2nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.3700
Day High
1.4300
Open 1.3800
Previous Close 1.4100 1.4100
Volume 4,312,900 4,312,900
Avg Vol 4,561,060 4,561,060
Stochastic %K 10.35% 10.35%
Weighted Alpha -44.88 -44.88
5-Day Change -0.2400 (-14.72%) -0.2400 (-14.72%)
52-Week Range 1.3500 - 3.9400 1.3500 - 3.9400
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 278,967
  • Shares Outstanding, K 197,849
  • Annual Sales, $ 332,310 K
  • Annual Income, $ -51,750 K
  • EBIT $ 54 M
  • EBITDA $ 56 M
  • 60-Month Beta 0.86
  • Price/Sales 0.86
  • Price/Cash Flow 59.94
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 162.10% ( +25.53%)
  • Historical Volatility 67.50%
  • IV Percentile 93%
  • IV Rank 34.36%
  • IV High 393.52% on 09/20/24
  • IV Low 40.97% on 06/13/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 313
  • Volume Avg (30-Day) 1,333
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 46,766
  • Open Int (30-Day) 56,638

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.18
  • Number of Estimates 5
  • High Estimate -0.13
  • Low Estimate -0.23
  • Prior Year 0.34
  • Growth Rate Est. (year over year) -152.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3500 +2.96%
on 04/01/25
Period Open: 1.7000
1.8600 -25.27%
on 03/04/25
-0.3100 (-18.24%)
since 02/28/25
3-Month
1.3500 +2.96%
on 04/01/25
Period Open: 2.2000
2.4000 -42.08%
on 01/14/25
-0.8100 (-36.82%)
since 01/02/25
52-Week
1.3500 +2.96%
on 04/01/25
Period Open: 2.8800
3.9400 -64.72%
on 12/09/24
-1.4900 (-51.74%)
since 04/02/24

Most Recent Stories

More News
Esperion Appoints Robert E. Hoffman to Board of Directors

ESPR : 1.3900 (-1.42%)
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference

ESPR : 1.3900 (-1.42%)
Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

ESPR : 1.3900 (-1.42%)
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y

Esperion Therapeutics ESPR incurred a fourth-quarter 2024 loss of 10 cents per share (excluding one-time expenses of loss on extinguishment of debt and exchange transaction), which was narrower than the...

ESPR : 1.3900 (-1.42%)
RIGL : 18.21 (+6.18%)
PCRX : 24.89 (+3.41%)
Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4

CEO Sheldon Koenig expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe and global expansion into key markets....

ESPR : 1.3900 (-1.42%)
XPH : 42.20 (+0.05%)
VTI : 277.95 (+0.79%)
IWM : 202.66 (+1.58%)
Esperion Therapeutics: Q4 Earnings Snapshot

Esperion Therapeutics: Q4 Earnings Snapshot

ESPR : 1.3900 (-1.42%)
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

ESPR : 1.3900 (-1.42%)
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

ESPR : 1.3900 (-1.42%)
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

ESPR : 1.3900 (-1.42%)
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ESPR : 1.3900 (-1.42%)

Business Summary

Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol).

See More

Key Turning Points

3rd Resistance Point 1.4833
2nd Resistance Point 1.4567
1st Resistance Point 1.4233
Last Price 1.3900
1st Support Level 1.3633
2nd Support Level 1.3367
3rd Support Level 1.3033

See More

52-Week High 3.9400
Fibonacci 61.8% 2.9506
Fibonacci 50% 2.6450
Fibonacci 38.2% 2.3394
Last Price 1.3900
52-Week Low 1.3500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades